CLIN CANCER RES:IncRNA-PVT1与FOXM1在胃癌生长侵袭中的作用

2017-04-21 MedSci MedSci原创

IncRNA PVT1是人类肿瘤表观遗传学的重要调节因子,有研究证实其可以促进胃癌进展,但是其在肿瘤发生发展过程中的作用机制尚需进一步研究。CLIN CANCER RES近期报道了一篇文章研究了PVT1在胃癌发生进展中的分子机制及其临床应用潜能。

IncRNA PVT1是人类肿瘤表观遗传学的重要调节因子,有研究证实其可以促进胃癌进展,但是其在肿瘤发生发展过程中的作用机制尚需进一步研究。CLIN CANCER RES近期报道了一篇文章研究了PVT1在胃癌发生进展中的分子机制及其临床应用潜能。

作者使用RT-qPCR方法分析了190例胃癌组织及临近正常胃粘膜组织(ANT)中PVT1表达水平。通过体内体外功能实验研究PVT1的生物学功能。通过RNA蛋白折叠实验及质谱分析实验检测与PVT1相互作用的蛋白FOXM1。蛋白质RNA免疫沉淀分析FOXM1与PVT1之间的作用。染色质免疫沉淀(ChiP)及荧光素酶分析寻找FOXM1与在PVT1启动子的结合位点。实验结果发现,与正常胃粘膜组织相比,胃癌中IncRNA PVT1表达明显升高。高表达PVT1与胃癌患者不良预后有关。在体内及体外实验中PVT1均会增强胃癌细胞增殖及侵袭能力。PVT1增加FOXM1翻译后表达。PVT1还是一种FOXM1反应性IncRNA,FOXM1直接连接到PVT1启动子激活其转录。

该研究表明PVT1通过与FOXM1作用促进肿瘤进展,PVT1可以作为胃癌预后的有效预测指标。PVT1-FOXM1反馈回路可以作为胃癌治疗的潜在治疗靶点。

原始出处:
Mi-die Xu,Yiqin Wang,et al.A Positive Feedback Loop of IncRNA-PVT1 and FOXM1 Facilitates Gastric Cancer Growth and Invasion.CLIN CANCER RES.April 2017 doi:10.1158/1078-0432.CCR-16-0742

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2054774, encodeId=deea2054e7474, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Thu Jan 18 08:41:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642804, encodeId=da3f164280428, content=<a href='/topic/show?id=165be622f0' target=_blank style='color:#2F92EE;'>#FOXM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7622, encryptionId=165be622f0, topicName=FOXM1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36ca23025609, createdName=ms3046638856685384, createdTime=Thu Mar 15 01:41:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005633, encodeId=27c6200563372, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jan 08 23:41:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792918, encodeId=cf2d1e929181f, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Nov 11 10:41:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190053, encodeId=6cfb190053b1, content=好文章学习并分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Apr 24 07:23:50 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
    2018-01-18 紫砂壶
  2. [GetPortalCommentsPageByObjectIdResponse(id=2054774, encodeId=deea2054e7474, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Thu Jan 18 08:41:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642804, encodeId=da3f164280428, content=<a href='/topic/show?id=165be622f0' target=_blank style='color:#2F92EE;'>#FOXM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7622, encryptionId=165be622f0, topicName=FOXM1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36ca23025609, createdName=ms3046638856685384, createdTime=Thu Mar 15 01:41:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005633, encodeId=27c6200563372, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jan 08 23:41:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792918, encodeId=cf2d1e929181f, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Nov 11 10:41:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190053, encodeId=6cfb190053b1, content=好文章学习并分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Apr 24 07:23:50 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2054774, encodeId=deea2054e7474, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Thu Jan 18 08:41:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642804, encodeId=da3f164280428, content=<a href='/topic/show?id=165be622f0' target=_blank style='color:#2F92EE;'>#FOXM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7622, encryptionId=165be622f0, topicName=FOXM1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36ca23025609, createdName=ms3046638856685384, createdTime=Thu Mar 15 01:41:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005633, encodeId=27c6200563372, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jan 08 23:41:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792918, encodeId=cf2d1e929181f, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Nov 11 10:41:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190053, encodeId=6cfb190053b1, content=好文章学习并分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Apr 24 07:23:50 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2054774, encodeId=deea2054e7474, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Thu Jan 18 08:41:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642804, encodeId=da3f164280428, content=<a href='/topic/show?id=165be622f0' target=_blank style='color:#2F92EE;'>#FOXM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7622, encryptionId=165be622f0, topicName=FOXM1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36ca23025609, createdName=ms3046638856685384, createdTime=Thu Mar 15 01:41:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005633, encodeId=27c6200563372, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jan 08 23:41:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792918, encodeId=cf2d1e929181f, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Nov 11 10:41:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190053, encodeId=6cfb190053b1, content=好文章学习并分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Apr 24 07:23:50 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
    2017-11-11 achengzhao
  5. [GetPortalCommentsPageByObjectIdResponse(id=2054774, encodeId=deea2054e7474, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Thu Jan 18 08:41:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642804, encodeId=da3f164280428, content=<a href='/topic/show?id=165be622f0' target=_blank style='color:#2F92EE;'>#FOXM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7622, encryptionId=165be622f0, topicName=FOXM1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36ca23025609, createdName=ms3046638856685384, createdTime=Thu Mar 15 01:41:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005633, encodeId=27c6200563372, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Mon Jan 08 23:41:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792918, encodeId=cf2d1e929181f, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Nov 11 10:41:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190053, encodeId=6cfb190053b1, content=好文章学习并分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Apr 24 07:23:50 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
    2017-04-24 大爰

    好文章学习并分享

    0

相关资讯

胃癌缘何成为上海第三高发的肿瘤

近日上海市疾控中心发布了上海市癌症指数——癌情通报。报告指出肿瘤已经是影响上海居民健康的主要慢性疾病之一,是上海居民的第二位死因。而在肿瘤相关死亡中胃癌位居第三。“啥,你说啥?胃癌不是‘穷病’吗?咱大上海可不穷啊!上海人可是蛮讲究饮食健康的。”在大家的印象中胃癌应该是个“穷病”,发达地区发病率低,欠发达地区发病率高。我们国家的西北地区,如甘肃、青海,是胃癌发病率最高的,然而上海作为国内经济发达地区

Am J Gastroenterol:早期胃癌内镜黏膜下剥离术治疗评分系统

eCura系统可以有效的预测不符合根治性的内镜黏膜下剥离术标准的胃癌患者进行手术后的生存率,而且单一的内镜黏膜下剥离术治疗患者发生淋巴结转移的风险较低

Gastroenterology:SPOCD1和BTN3A2为胃癌风险变异

SPOCD1与BTN3A2在胃癌的发生起关键作用

Oncogene:中科院周兆才研究组阐明胃癌发生相关Hippo通路关键转录因子TEAD4特异性结合DNA机制

近日,国际学术权威刊物自然出版集团旗下子刊、肿瘤学重要学术期刊《Oncogene》杂志在线发表了中国科学院生物化学与细胞生物学研究所/分子细胞科学卓越创新中心周兆才研究组的最新研究成果“DNA-binding mechanism of the Hippo pathway transcription factor TEAD4”。研究在原子水平上阐明了Hippo信号通路下游关键转录因子TEAD4特异性

Ann Surg:胃癌切除术后是Roux-en-Y术式好还是Billroth II术式好?

目前手术是治疗胃癌的主要手段,DG后的重建技术仍然存在着争议。Billroth II(B-II)和Roux-en-Y(R-Y)都是目前流行的手术方法。近期,一项发表在杂志Ann Surg上的文章旨在比较胃癌患者进行远端胃大部切除术(DG)后进行B-II和R-Y重建术后的临床症状。此项研究是一项前瞻性多中心随机对照试验。从2008年10月至2014年10月,接受DG治疗的162例患者被随机分配到B-

Cancer Cell:日美研究团队发现神经紧张加快胃癌形成机理

神经细胞不仅存在于大脑,而且遍布于人体全身。在胃肠部位有1亿多个各种各样的神经细胞,对胃肠活动和消化荷尔蒙的分泌进行调节。此前,人们虽然强调神经紧张会引起癌症和各种各样的疾病,但其原因及重要性却不甚了知。日本东京大学与美国哥伦比亚大学的联合研究团队利用转基因技术,使小鼠消化道内负责分泌神经信号传递物质乙酰胆碱的神经细胞发出绿光,从而成功观察到乙酰胆碱从何而来。结果显示,分泌乙酰胆碱的神经细胞环绕于